Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lyme disease
Biotech
Valneva to lay off up to 15%, faces tough travel vaccine market
Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.
James Waldron
May 13, 2026 8:35am
Why Valneva CEO remains bullish on Pfizer-partnered Lyme vaccine
Apr 1, 2026 3:00pm
Pfizer, Valneva miss Lyme shot ph. 3 goal but plan approval push
Mar 23, 2026 6:45am
Pfizer, Valneva boosted by updated Lyme vaccine data
Sep 3, 2025 10:19am
Pfizer, Valneva show Lyme disease shot effective for 2nd booster
Sep 3, 2024 4:30am
Pfizer, Valneva overcome CRO Lyme disease recruitment problems
Dec 5, 2023 3:20pm
